Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [64Cu]Cu-NOTA-ch14.18/CHO.
Trautwein NF, Schwenck J, Seitz C, Seith F, Calderón E, von Beschwitz S, Singer S, Reischl G, Handgretinger R, Schäfer J, Lang P, Pichler BJ, Schulte JH, la Fougère C, Dittmann H. Trautwein NF, et al. Among authors: handgretinger r. Theranostics. 2024 Jan 20;14(3):1212-1223. doi: 10.7150/thno.92481. eCollection 2024. Theranostics. 2024. PMID: 38323317 Free PMC article.
Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma.
Schmitt J, Schwenck J, Maurer A, Przybille M, Sonanini D, Reischl G, Wehrmüller JE, Quintanilla-Martinez L, Gillies SD, Krueger MA, Schaefer JF, la Fougère C, Handgretinger R, Pichler BJ. Schmitt J, et al. Among authors: handgretinger r. Theranostics. 2022 Jul 18;12(13):5615-5630. doi: 10.7150/thno.56736. eCollection 2022. Theranostics. 2022. PMID: 35966592 Free PMC article.
First-in-Humans PET/MRI of In Vivo GD2 Expression in Osteosarcoma.
Trautwein NF, Reischl G, Seitz C, Dittmann H, Seith F, Scheuermann S, Feuchtinger T, Dombrowski F, Handgretinger R, Fuchs J, Pichler B, Fougère C, Schwenck J. Trautwein NF, et al. Among authors: handgretinger r. J Nucl Med. 2023 Feb;64(2):337-338. doi: 10.2967/jnumed.122.264626. Epub 2022 Sep 15. J Nucl Med. 2023. PMID: 36109181 Free PMC article. No abstract available.
GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells.
Seitz CM, Schroeder S, Knopf P, Krahl AC, Hau J, Schleicher S, Martella M, Quintanilla-Martinez L, Kneilling M, Pichler B, Lang P, Atar D, Schilbach K, Handgretinger R, Schlegel P. Seitz CM, et al. Among authors: handgretinger r. Oncoimmunology. 2019 Nov 7;9(1):1683345. doi: 10.1080/2162402X.2019.1683345. eCollection 2020. Oncoimmunology. 2019. PMID: 32002293 Free PMC article.
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
Seitz CM, Flaadt T, Mezger M, Lang AM, Michaelis S, Katz M, Syring D, Joechner A, Rabsteyn A, Siebert N, Troschke-Meurer S, Zumpe M, Lode HN, Yang SF, Atar D, Mast AS, Scheuermann S, Heubach F, Handgretinger R, Lang P, Schlegel P. Seitz CM, et al. Among authors: handgretinger r. Front Immunol. 2021 Jul 22;12:690467. doi: 10.3389/fimmu.2021.690467. eCollection 2021. Front Immunol. 2021. PMID: 34367149 Free PMC article. Clinical Trial.
Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
Flaadt T, Ladenstein RL, Ebinger M, Lode HN, Arnardóttir HB, Poetschger U, Schwinger W, Meisel R, Schuster FR, Döring M, Ambros PF, Queudeville M, Fuchs J, Warmann SW, Schäfer J, Seitz C, Schlegel P, Brecht IB, Holzer U, Feuchtinger T, Simon T, Schulte JH, Eggert A, Teltschik HM, Illhardt T, Handgretinger R, Lang P. Flaadt T, et al. Among authors: handgretinger r. J Clin Oncol. 2023 Jun 10;41(17):3135-3148. doi: 10.1200/JCO.22.01630. Epub 2023 Feb 28. J Clin Oncol. 2023. PMID: 36854071 Free PMC article. Clinical Trial.
Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3).
Arendt AM, Heubach F, Maier CP, Giardino S, Jung G, Kowalewski E, Rabsteyn A, Amorelli G, Seitz C, Schlegel P, Handgretinger R, Lang P. Arendt AM, et al. Among authors: handgretinger r. Cancer Immunol Immunother. 2023 Nov;72(11):3813-3824. doi: 10.1007/s00262-023-03536-x. Epub 2023 Sep 24. Cancer Immunol Immunother. 2023. PMID: 37742286 Free PMC article.
544 results